Tevogen Bio Inc. (TVGN)
NASDAQ: TVGN
· Real-Time Price · USD
0.98
-0.05 (-4.85%)
At close: May 01, 2025, 3:59 PM
0.97
-0.53%
After-hours: May 01, 2025, 06:14 PM EDT
-4.85% (1D)
| Bid | 0.96 |
| Market Cap | 179.31M |
| Revenue (ttm) | 396.59K |
| Net Income (ttm) | -13.73M |
| EPS (ttm) | -0.07 |
| PE Ratio (ttm) | -13.93 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.99 |
| Volume | 1,482,039 |
| Avg. Volume (20D) | 954,875 |
| Open | 1.01 |
| Previous Close | 1.03 |
| Day's Range | 0.96 - 1.06 |
| 52-Week Range | 0.26 - 3.09 |
| Beta | -0.82 |
About TVGN
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey....
Industry Biotechnology
Sector Healthcare
IPO Date Jan 5, 2022
Employees 18
Stock Exchange NASDAQ
Ticker Symbol TVGN
Website https://tevogen.com
Analyst Forecast
According to 1 analyst ratings, the average rating for TVGN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 925.54% from the latest price.
Stock Forecasts3 days ago
+7.74%
Tevogen Bio Holdings shares are trading higher aft...
Unlock content with
Pro Subscription
2 days ago
-5.52%
Tevogen Bio Holdings shares are trading higher after the company reaffirmed its oncology pipeline revenue forecast, projecting $1 billion in its launch year and a cumulative five-year estimate of $10 billion to $14 billion.
